Market Access and Reimbursement
We are health economics consultants who provide end-to-end market access and reimbursement advisory services to support funding across PBS, MBS and Prescribed List pathways. Our work is informed by former PBAC and MSAC evaluator experience, ensuring strategies and submissions are built for real-world scrutiny and decision-making.
Decision context
This service supports decisions about reimbursement pathways, evidence positioning, pricing strategy and timing of market entry across the PBS, MBS and Prescribed List. These decisions are typically made under conditions of uncertainty, evolving HTA standards and committee judgement — so how evidence is framed and interpreted can be as important as the evidence itself.
Select a pathway below to explore our detailed FAQs and navigate the Australian HTA landscape with confidence:
Our role
Pulse Economics helps pharmaceutical, biotech, medtech and diagnostics sponsors navigate market access and reimbursement pathways with clarity, realism and decision-readiness.
Our advice is shaped by first-hand PBAC and MSAC submission evaluation experience, meaning we understand not only what is required, but how submissions are assessed in practice, where scrutiny is applied, and where risks typically emerge.
We work with clients to anticipate committee concerns, clarify trade-offs, and design strategies that are robust to evaluation and policy scrutiny.
What we deliver in practice
Our market access and reimbursement support includes:
- PBAC, MSAC and Prescribed List pathway assessment and strategic advice
- Comparator, endpoint and PICO framework strategy
- Evidence positioning aligned to committee decision-making frameworks
- Submission design, drafting, review and response to evaluation issues
- Reimbursement and payer positioning across public and private markets
- Strategic advice across pre-submission, submission and post-decision phases
All deliverables are tailored to the decision context, product maturity and evidence base.
Our approach
What differentiates Pulse Economics is not just technical capability, but how we interpret and integrate evidence for decision-making.
Our approach is:
- Evaluator-informed: grounded in experience assessing PBAC and MSAC submissions
- Decision-focused: built for committee deliberation, not just guideline compliance
- Integrated: linking clinical evidence, economic modelling and policy context
- Pragmatic: recognising uncertainty, constraints and real-world trade-offs
We focus on developing decision-ready strategies rather than technically correct but fragile submissions.
Where this service applies
This service is relevant across the full product lifecycle, including:
- Early development and pathway planning
- Pre-submission strategy and evidence positioning
- Initial and resubmission support
- Post-decision strategy and lifecycle management
We work with both early-stage innovators and established organisations, tailoring our advice accordingly.
Why Pulse Economics
- Direct experience evaluating PBAC and MSAC submissions
- Deep understanding of Australian HTA and reimbursement decision processes
- Strong integration with evidence strategy and economic modelling
- Clear, defensible advice grounded in how decisions are actually made
Explore how we can support your market access pathway
Read more of our Insights on Market Access & Reimbursement…
